Gilead sees Q2 EPS hit from IPR&D expenses

3 hours ago 1

Gilead Sciences (NASDAQ:GILD) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process research and development (IPR&D) charges, leading to a ~($0.04) reduction in GAAP and non-GAAP EPS.
The company said ~$40M of the charge

Recommended For You